Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Shares Outstanding (Weighted Average) (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Shares Outstanding (Weighted Average) readings, the most recent being $99.0 million for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 2.66% to $99.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $99.0 million, a 2.66% increase, with the full-year FY2024 number at $99.0 million, up 2.66% from a year prior.
  • Shares Outstanding (Weighted Average) hit $99.0 million in Q3 2025 for Goldenwell Biotech, up from $9.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $99.0 million in Q4 2024 to a low of $9.9 million in Q1 2025.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $96.4 million (2022), compared with a mean of $85.1 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 14.15% in 2021 and later plummeted 89.73% in 2025.
  • Goldenwell Biotech's Shares Outstanding (Weighted Average) stood at $91.3 million in 2021, then grew by 5.6% to $96.4 million in 2022, then changed by 0.0% to $96.4 million in 2023, then increased by 2.66% to $99.0 million in 2024, then changed by 0.0% to $99.0 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $99.0 million (Q3 2025), $9.9 million (Q2 2025), and $9.9 million (Q1 2025) per Business Quant data.